Full Press Release Details
Demonstrates Prognostic Utility in TransATAC Cohort
New York, March 1, 2022 - Tiziana Life
Sciences Ltd.'s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today
announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER is highly prognostic for risk
of distant recurrence in women with breast cancer.
Investigators from the European Institute of Oncology
(IEO) in Milan and The Royal Marsden Hospital in London evaluated 776 tumor samples from the TransATAC cohort, a subgroup of estrogen
receptor positive (ER+), post-menopausal patients from the prospective, randomized ATAC trial. The pivotal TransATAC study has been used
to evaluate many of the commonly used breast cancer risk scoring assays, including OncotypeDX, Prosigna, EndoPredict and Breast Cancer
In this analysis, investigators demonstrated that
patients with a StemPrintER Risk Score (SPRS) Low result had significantly better outcomes than patients with a SPRS High result. Patients
with a SPRS Low result had a 5.8% risk of distant recurrence at 10 years versus 23.2% risk of distant recurrence in patients with a SPRS
"Many genomic classifiers have been evaluated
in the TransATAC cohort," said Salvatore Pece, Full Professor at the Milan University Medical School and Director of the Hormone-Related
Cancers and Stem Cell Pathobiology Lab at IEO. "It is exciting that StemPrintER appears to perform as well as other commercially-available
tests and indicates the potential for this novel test to inform clinical decision making."
Forward-Looking Statements
This press release contains
"forward-looking statements" Forward-looking statements reflect our current view about future events. When used in this press
release, the words "anticipate," "believe," "estimate," "expect," "future,"
"intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management,
identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating
to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based
on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking
statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to
predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements
of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking
statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include,
without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights;
the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability
to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions;
and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those
anticipated, believed, estimated, expected, intended or planned.
Factors or events that
could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot
guarantee future results, levels of activity, performance or achievements. Tiziana Life Sciences Ltd. assumes no obligation to update
any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Tiziana Life Sciences Ltd
Hana Malik, Business Development, and Investor
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC